A Study of Lorigerlimab in Participants With Advanced Solid Tumors
← catalyst calendarNCT06730347 · readout ≤ 345 d
Sponsored by MacroGenics (industry) · MGNX — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
80estimated
Sites
16
Countries
Canada, South Korea, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-01 | actual | When the study began enrolling |
| Primary completion | Jul 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Platinum-resistant Ovarian Cancer
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Clear Cell Adenocarcinoma of Ovary
- Clear Cell Adenocarcinoma of Vulva
- Clear Cell Adenocarcinoma of Vagina
- Clear Cell Adenocarcinoma of Cervix
- Clear Cell Adenocarcinoma of Uterus
- Clear Cell Adenocarcinoma of Fallopian Tube
- Clear Cell Adenocarcinoma of Peritoneum
- Endometrial Cancer
Intervention
- Biological: Lorigerlimab — also filed as MGD019
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as determined by the investigator
measured Throughout the study up to approximately 2 years
Permalink · MGNX's whole pipeline · Catalyst calendar · Every registered study · What changed